



28th December 2021

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001 Scrip Code: BSE – AJANTPHARM 532331	National Stock Exchange of India Exchange Plaza, 5 th Floor, Plot No. C/1, G block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: NSE AJANTPHARM
--	---

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“Listing Regulations”)

Sub: Outcome of the Meeting of Board of Directors of Ajanta Pharma Limited (“Company”)

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e., December 28, 2021, has *inter-alia* unanimously approved Buy-back of up to 11,20,000 fully paid-up Equity Shares of face value of ₹ 2/- each by the Company (representing 1.29% of the total number of Equity Shares of the Company) at a price of ₹ 2,550/- (Rupees Two Thousand Five Hundred and Fifty only) per Equity Share payable in cash for a total consideration not exceeding ₹ 285.60 crores (Rupees Two Hundred Eighty Five Crores and Sixty Lakhs only) (excluding transaction costs such as fees, brokerage, taxes, duties, etc.), which is not exceeding 10% of the total paid-up equity share capital and free reserves (including securities premium account) as per the audited financial statements of the Company for the financial year ended on March 31, 2021, through the “**Tender Offer**” route as prescribed under the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 as amended, on a proportionate basis, from the Equity Shareholders/beneficial owners of the Equity Shares of the Company including promoters, members of promoter group and persons acting in concert, as on the record date.

The Board Meeting commenced at 10.00 a.m. and concluded at 11.15 a.m.

The Pre Buy-back shareholding pattern of the Company as on 24th December 2021 is enclosed herewith alongwith Press Release on the buy-back of shares.

Kindly take this disclosure on record and disseminate.

Thanking you,

Yours faithfully,

Gaurang Shah
VP – Legal & Compliance Officer

Encl: a/a



Pre Buy-Back Shareholding Pattern

Category of Shareholder	Number of Shares	% to existing Equity Share capital
Promoters and Promoter Group	6,08,69,823	70.34 %
Public Shareholding	2,56,65,947	29.66 %
Total	8,65,35,770	100.00 %

Press Release**Ajanta Pharma announces Rs. 356 cr. buyback
of equity shares**

(Including tax on buy back of equity shares)

Mumbai, 28th December 2021: The Board of Directors of Ajanta Pharma Ltd. a specialty pharmaceutical formulation company, approved today buyback of up to 11,20,000 fully paid-up Equity Shares of face value of Rs. 2/- each by the Company at a price of Rs. 2,550/- per Equity Share payable in cash.

The total pay-out towards buyback of shares will be not exceeding Rs. 356 crores (equity shares buyback consideration not exceeding Rs. 286 crores + buyback tax not exceeding Rs. 70 crores) on a proportionate basis through the tender offer process.

This buyback represents 1.29% of the total number of equity shares of the company and 9.89% of the paid-up share capital and free reserves of the company as per the audited financial statements for the financial year ended on March 31, 2021.

Record date for the same has been fixed as 14th January 2022.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1st to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai. Company has 8 world class manufacturing facilities located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its Revenue from Operations growing at 17% CAGR and Net Profit at 27% CAGR.

For more details visit www.ajantapharma.com

For regular updates follow us on twitter– www.twitter.com/ajantapharmaltd

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

Abhineet Kumar Tel: +91 22 66061814 Email: abhineet.kumar@ajantapharma.com

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331
Corporate Identity Number (CIN): L24230MH1979PLC022059

Safe Harbour Statement